Swedish aerosol research specialists Inhalation Sciences AB (ISAB) have announced a new partnership with German OINDP development company Actarmo Medical to offer development services for inhalation products from preclinical through formulation and device development and clinical trial supplies. ISAB says that the partnership is part of a new emphasis on its Inhalation Research Services CRO unit, a transition from focusing on its aerosol testing products, including PreciseInhale, DissolvIt, and XposeAli.
According to the announcement, “Actarmo Medical has an established client base and highly valued specialist expertise in formulation development, analytical testing under full GMP, MDR consultancy and consultancy for all aspects of inhaler delivery devices.”
ISAB CEO Manoush Masarrat commented, “I am very pleased with this collaboration and confident that few service providers in the field will be able to offer a comparative level of expertise. Our teams share the same values and commitment, whilst bringing together a hugely competitive range of capabilities. The joint customer projects have so far proven to be very successful, and this partnership will enrich both organizations and our customers.”
Actarmo Medical CEO Thomas Weuthen said, “Actarmo Medical and ISAB work in complementary areas of the drug development and the combined range of services will be very appealing to customers, simplifying their inhalation drug product development process. ISAB’s services do fill a gap we have seen several times within our projects, and we are happy to now work closely with ISAB. This collaboration brings us new customers which we did not address until now and I am really looking forward to this cooperation!”
Read the ISAB press release.
